PACS Group (PACS) Shares Rise +24% on Acquisition News and Solid Q1 Results
Key Takeaways
- PACS Group shares surged approximately 24% over the past 30 days, climbing from $36.25 on June 15 to $44.95 on July 14, 2026.
- The primary catalyst was the announcement of a definitive agreement to acquire operations of 34 skilled nursing facilities across six western states from Eduro Healthcare.
- Strong first-quarter 2026 results — featuring 11.2% revenue growth and a 184% surge in net income — continued to fuel bullish sentiment and upward analyst revisions.
- A $250 million share repurchase authorization and significant institutional accumulation reinforced investor confidence in the company's trajectory.
- Analyst consensus remains favorable, with price targets ranging from $44 to $52 and a "Moderate Buy" rating across seven covering firms.
- Ongoing legal proceedings related to prior Medicare billing allegations remain a risk factor that investors continue to monitor.
Understanding PACS Group's Business and Market Position
PACS Group, Inc. is one of the largest post-acute healthcare platforms in the United States. Founded in 2013 and headquartered in Salt Lake City, Utah, the company — through its independent operating subsidiaries — owns, leases, and operates more than 320 skilled nursing facilities and senior living communities across 17 states, serving over 31,700 patients daily. PACS employs a decentralized, locally-led operating model in which facility administrators function as quasi-CEOs, supported by centralized back-office services including clinical consulting, legal, and technology infrastructure. The company's core growth strategy centers on acquiring underperforming post-acute facilities, improving clinical quality and operational efficiency, and holding those assets to compound cash flow over time. Skilled nursing services account for approximately 96% of routine revenue, with Medicare and Medicaid representing roughly 74% of payer mix.
Recent Stock Performance of PACS Group (PACS): The Last 30 Days and Quarter
PACS stock closed at $44.95 on July 14, 2026, representing a 24.0% gain from the June 15 close of $36.25. The 30-day rally was not linear; shares touched a near-term low of $34.33 on June 10 before mounting a sustained advance driven by acquisition news and ongoing positive sentiment from the company's first-quarter earnings beat. Over the trailing quarter, the stock has climbed approximately 26.5% from $35.54 at the start of June, underscoring a broader multi-month uptrend. The stock now trades near its 52-week high of $45.89 and remains well above its 20-day, 50-day, 100-day, and 200-day simple moving averages. Notably, PACS has maintained a bullish golden cross pattern since October 2025, with the 50-day moving average consistently above the 200-day moving average. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Key Drivers Behind PACS Stock's Recent Gains
The dominant catalyst during the 30-day window was the June 29 announcement that PACS subsidiaries entered into a definitive agreement to acquire the operations of 34 skilled nursing facilities from Eduro Healthcare, a family-owned operator with a nearly 20-year history. The portfolio spans 3,633 skilled nursing beds across Texas (22 facilities), Montana (6), South Dakota (3), and one facility each in New Mexico, North Dakota, and Utah. The deal expands PACS into four new states and was viewed by the market as a strong validation of the company's acquisition-and-improvement operating playbook. Shares jumped more than 7% on the day following the announcement.
Beyond the acquisition, sustained tailwinds from first-quarter 2026 earnings continued to support the stock. Reported on May 11, Q1 results showed revenue of $1.42 billion — an 11.2% year-over-year increase — and net income of $80.7 million, a 184% jump from $28.4 million in the prior-year period. Adjusted EBITDA rose 74.6% to $170.4 million. Same-store skilled nursing revenue grew 8.0%, skilled-nursing occupancy reached 90.9%, and mature facilities averaged 4.4 CMS stars. The company also raised full-year 2026 adjusted EBITDA guidance to a range of $605 million to $625 million.
Institutional activity provided additional support. Alyeska Investment Group increased its position by 159.5%, Crewe Advisors by 93.1%, and Royce & Associates by 76.6%. Meanwhile, the board's $250 million share repurchase authorization, announced alongside Q1 results, signaled management confidence in the stock's valuation. On the analyst front, Truist Financial raised its price target to $52, Oppenheimer to $48, RBC to $52, and UBS to $44 — with five Buy ratings and two Holds forming a consensus "Moderate Buy."
Broader Factors Supporting PACS Over the Quarter
The broader quarterly narrative reflects a company successfully transitioning from a turnaround story to an execution-and-scale story. The first-quarter earnings beat in mid-May served as a critical inflection point, delivering concrete evidence that PACS's fix-and-hold operating model — targeting underperforming facilities, raising clinical quality, improving occupancy and payer mix, and compounding cash flow — was generating measurable results at scale. The subsequent analyst upgrades, guidance raise, and buyback authorization created a reinforcing cycle of positive sentiment. The late-June Eduro acquisition announcement added a growth dimension to what had been primarily an operational-improvement thesis. Despite the overhang of a pending securities lawsuit related to historical Medicare billing practices — for which defendants filed a motion to dismiss in February 2026 — the market has largely focused on the company's improving operational metrics and expanding footprint. The stock's removal from several Russell Value indexes in late June created some passive-fund rebalancing but did not derail the upward momentum.
Exploring Systematic Approaches with Tickeron AI Tools
For traders seeking systematic approaches to identify opportunities in stocks like PACS Group, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of automated trading bots that collectively trade thousands of tickers across various timeframes, strategies, and performance profiles. Rather than displaying every available bot, the Trending AI Robots section highlights only those that have recently demonstrated top-tier performance and relevance in current market conditions. These bots range from short-term momentum strategies to longer-term swing trading and trend-following approaches, allowing users to evaluate bots based on historical performance metrics, risk parameters, and strategy alignment. Exploring this curated list can help traders discover data-driven tools aligned with their investment style. In my view, this resource provides a practical way to incorporate quantitative signals into ongoing research without replacing fundamental analysis.
Looking Ahead: Factors to Monitor for PACS Stock
Looking ahead, several factors will shape PACS Group's stock trajectory. The integration of the 34 Eduro facilities — expected to close in tranches primarily during the third quarter of 2026 — will be closely scrutinized for evidence that management can extend its operating playbook across a larger, more geographically diverse portfolio without diluting clinical quality or financial discipline. The company's next earnings report, estimated around early August 2026, will provide a critical checkpoint on same-store metrics, occupancy trends, skilled mix, and the durability of margin expansion. Investors should also monitor developments in the pending securities litigation, as any adverse rulings could reintroduce risk premiums. On the macroeconomic front, potential changes to Medicare and Medicaid reimbursement frameworks remain an evergreen risk for the post-acute care sector, given that government payers represent the majority of PACS revenue. Additionally, the pace and scale of insider selling — over 380,000 shares sold in the last 90 days, predominantly under pre-arranged 10b5-1 plans — will remain a data point for investors evaluating management alignment with shareholder interests.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PACS in downward trend: price dove below 50-day moving average on September 11, 2026
PACS moved below its 50-day moving average on September 11, 2026 date and that indicates a change from an upward trend to a downward trend. In 15 of 19 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 79%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for PACS entered a downward trend on September 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on PACS as a result. In 30 of 37 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for PACS just turned positive on October 02, 2026. Looking at past instances where PACS's MACD turned positive, the stock continued to rise in 12 of 15 cases over the following month. The odds of a continued upward trend are 80%.
Following a +2.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where PACS advanced for three days, in 105 of 128 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 35 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. PACS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.139) is normal, around the industry mean (208.195). P/E Ratio (25.181) is within average values for comparable stocks, (175.456). Projected Growth (PEG Ratio) (1.085) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.209) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement